Open-label trial to evaluate the efficacy and safety of the use of argatroban in patients with heparin-induced thrombocytopenia.

Trial Profile

Open-label trial to evaluate the efficacy and safety of the use of argatroban in patients with heparin-induced thrombocytopenia.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Argatroban (Primary)
  • Indications Heparin-induced thrombocytopenia and thrombosis syndrome
  • Focus Adverse reactions
  • Acronyms ARG-HIT-CVD
  • Most Recent Events

    • 12 Nov 2008 Additional trial acronym ARG-HIT-CVD identified as reported by ClinicalTrials.gov.
    • 11 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top